As per a recent report in The Lancet, the incidence of prostate cancer is expected to double in India over the next few years. A crucial weapon in averting a severe health catastrophe will be early detection. But before addressing the issue of testing, there’s a knotty ribbon problem to be solved.
Related Posts
healthcare: Not ‘arms and legs’, healthcare companies are using AI to make ‘brains’: health-tech expert Yan Chow
Yan Chow, global healthcare leader, Automation Anywhere Synopsis The healthcare industry is on the verge of a transformation due to the increasing demands and the challenges it faces. Historically, advances in healthcare technology benefited billing and regulatory entities. Doctors and nurses were often the last to adopt new tools. AI is changing this dynamic, as […]
narayana hrudayalaya: Narayana Hrudayalaya’s shares are on a growth beat. What’s driving the hospital chain’s optimism?
Synopsis Improving financials of hospital chains, future growth prospects of the sector itself have attracted investors to hospital stocks. But while Apollo Hospitals and Max Healthcare led the gains post Covid-19, this calendar year Narayana Hrudayalaya has outperformed other major hospital stocks with a 72% rise in its share price. What lies ahead for the […]
As Novo Nordisk scales back, Eris and Biocon Biologics hit the sweet spot in India’s insulin market
“It is a small emergency,” says Amit Bakshi, chairman of Ahmedabad-based drugmaker Eris Lifesciences. He points to the recent decision of Novo Nordisk, the world’s top seller of insulin, to gradually phase out a popular product from India and several other markets as a part of global strategy. Weeks ago, Abbott Labs, the marketing partner […]
